1,445 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis Announces Positive Long-Term Data on Migraine Drug http://www.zacks.com/stock/news/509529/novartis-announces-positive-long-term-data-on-migraine-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509529 Sep 09, 2019 - Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year? http://www.zacks.com/stock/news/514961/has-novartis-nvs-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-514961 Sep 12, 2019 - Is (NVS) Outperforming Other Medical Stocks This Year?
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert http://www.zacks.com/stock/news/520833/breast-cancer-drugs-may-inflame-lungs-per-fda-safety-alert?cid=CS-ZC-FT-analyst_blog|industry_focus-520833 Sep 16, 2019 - The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Novartis Announces New Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/522872/novartis-announces-new-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-522872 Sep 17, 2019 - Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza http://www.zacks.com/stock/news/526375/biogens-new-study-to-test-higher-dose-of-sma-drug-spinraza?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526375 Sep 19, 2019 - Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy http://www.zacks.com/stock/news/533672/biogens-two-ms-drugs-get-chmp-nod-for-use-in-pregnancy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-533672 Sep 24, 2019 - Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Incyte Treats First Patient in Phase III Vitiligo Study http://www.zacks.com/stock/news/536926/incyte-treats-first-patient-in-phase-iii-vitiligo-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-536926 Sep 26, 2019 - Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Novartis Reports Additional Data on Spondylitis Drug Cosentyx http://www.zacks.com/stock/news/547460/novartis-reports-additional-data-on-spondylitis-drug-cosentyx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-547460 Oct 03, 2019 - Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration http://www.zacks.com/stock/news/552912/astrazenecas-fasenra-gets-fda-nod-for-self-administration?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552912 Oct 07, 2019 - The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Novartis' (NVS) Wet AMD Drug Beovu Obtains FDA Approval http://www.zacks.com/stock/news/556356/novartis-nvs-wet-amd-drug-beovu-obtains-fda-approval?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556356 Oct 09, 2019 - Novartis (NVS) wins FDA approval for Beovu injection for the treatment of wet AMD at a three-month dosing interval.
<<<Page 141>